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Introduction 
Trigeminal neuralgia (TN) is the most common neuralgia 
of the head and neck region and is a major cause of 
orofacial pain.1,2 TN was first described by John Locke in 
1677. Nicolas Andre later described TN by the term tic 
doloreaux,1 which means painful spasm. This term has 
also been accepted as an alternative name for TN.1-5 
Averagely, 4 out of 100 000 individuals develop TN 
annually.1,4,6 Occurrence of idiopathic TN before the age of 
40 years is rare.2 But it is common among the middle aged 
and the elderly after the age of 50 years.1,2,7-9 Moreover, 
TN is more common among females.4,5,7,10 Pain in TN is 
acute and striking, with sudden onset and termination. 
It is often described to be similar to electric shock, 
perforating, penetrating, superficial and sharp.3,6,8-10 
Pain strikes may be spontaneous or triggered.1-4 Most 
patients, but not all, have a trigger zone. Trigger zone is 
pathognomonic for TN. Most common sites include peri-
nasal skin, peri-oral skin, lips, nasolabial fold, gingiva 
and alveoli. Other areas such as cheeks, eyebrows, peri-
orbital skin and tongue may also serve as trigger zones. 
Most patients localize their trigger zone and avoid its 
stimulation.4-7,10,11 Stimulation often occurs by contact 
(skin and mucosa) and less commonly by movement.1,5 
Pain is often unilateral3,8,9,12 and does not cross the midline. 
Pathogenesis of TN is not well understood.1-3 Vascular 
pressure is the main cause of demyelination of nerves 
compressing the trigeminal nerve when entering the 
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Abstract
Introduction: Trigeminal neuralgia (TN) is the most common neuralgia in the head and neck 
region and a common cause of orofacial pain. It is routinely treated with carbamazepine. Laser, 
acupuncture and radiofrequency are among other treatment modalities for this condition. This 
study sought to assess the efficacy of laser therapy in conjunction with carbamazepine for treatment 
of TN.
Methods: A total of 30 patients who met the inclusion criteria were divided into 2 groups of cases 
and controls (n = 15) by double blind randomized controlled clinical trial. All patients received 100 
mg carbamazepine at baseline and another 100 mg after 2 days for pain control. In the case group, 
low level laser therapy (LLLT) was also performed in addition to pharmaceutical therapy. Sham laser 
was used in the control group instead of LLLT. Treatment was continued for 9 sessions (3 days a 
week). The intensity of pain was measured and compared in the 2 groups using visual analog scale 
(VAS) in 3 period. The qualitative variables among the groups were compared using the repeated 
measures analysis of variance (ANOVA).
Results: The severity of pain was lower at the end of treatment in the case compared to the control 
group so this difference was statistically significant (P = 0.003). The severity of pain decreased in 
both groups over time. Significant difference was noted in this regard between the 2 groups either 
(P = 0.003). At the end of treatment pain intensity dropped in the intervention group from 6/8 to 1/2 
and control group from 6/6 to 2/7.
Conclusion: Laser therapy did add to the value of pharmaceutical therapy for treatment of TN. Both 
groups experienced significant improvement over time. So it is better to used laser complementary 
therapy to reduce side effects and the medicine dosage.
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pons.1,3-5 This is where peripheral nervous system myelin 
sheath is terminated and central nervous system myelin 
sheath covers the nerves.1 Since TN is severely painful, 
accurate diagnosis and prompt treatment are of utmost 
importance. Diagnosis of TN is based on taking a precise 
history of the pain attacks. Also, evaluation of history is 
essential to rule out other causes of orofacial pain.4
There is no diagnostic test for definite diagnosis of TN. 
Even magnetic resonance imaging cannot definitely 
confirm the diagnosis of TN.1-3 Although radiography 
and referral for specific tests for other conditions may be 
required to rule out differential diagnoses, diagnosis of 
TN is completely clinical4 and interview with the patient 
and a thorough clinical examination will often suffice to 
make a diagnosis. 
Treatment of TN is primarily pharmaceutical.2,4,13,14 
Clinically, it has been documented that anticonvulsant 
drugs are effective for alleviation of neuropathic pains 
especially those described as burning or perforating pain. 
Thus, anticonvulsant drugs are mainly prescribed for TN.7 
Use of carbamazepine to alleviate pain due to TN 
has a long history. Many controlled and uncontrolled 
clinical trials and meta-analyses support prescription of 
carbamazepine as the first line treatment for TN.3,4,8,15 
Thus, carbamazepine is considered as the gold standard 
first line treatment for TN.3,7,11,16,17 In therapeutic doses, 
carbamazepine blocks the sodium channels and decreases 
the synaptic transmission.5,11 Carbamazepine has side 
effects such as imbalance,5,11 nausea,3,11,15 sleepiness,3,11 
confusion,5 dizziness11,13 and loss of appetite.3,11 
In 10% of patients, transient leukopenia15,18 and 
thrombocytopenia15,18 may occur. Patients who have low 
level of white blood cells prior to treatment are at higher 
risk of developing leukopenia.15,18 
Low level lasers decrease acute and chronic pains via 
different mechanisms such as decreasing the level of 
histamine, acetyl choline, serotonin, bradykinin and 
prostaglandin E2, increasing acetyl choline esterase, 
lymphatic drainage, ATP, aerobic metabolism, pain 
threshold, beta-endorphins and enkephalins, balancing 
the activity of adrenaline- noradrenaline and decreasing 
the production of P substance in the posterior spinal 
horn.14,17,19-21 
Laser irradiation dilates the capillaries and increases the 
drainage of fluids in the interstitial space by stimulating 
their reuptake. It exerts its analgesic effect by breaking the 
vicious cycle of contraction-edema-pain. Electromagnetic 
laser energy increases the metabolism of the injured 
tissue. This effect is enhanced by increased production of 
ATP and repolarization of cell membrane. Laser decreases 
the release of substances that stimulate pain receptors and 
significantly increases the pain threshold by stimulating 
the synthesis of endorphins.22 This study aimed to 
compare the severity of pain in patients with TN under 
treatment with carbamazepine with and without laser 
irradiation. 
Methods 
This double blind randomized controlled clinical trial 
was conducted on 30 patients with TN. Sample size 
was calculated to be 30 patients (n = 15 in each group) 
according to a previous study by Amanat et al in 2013.23 
The patients were selected among those presenting to 
Laser Center of Pardis International Campus, Tehran 
University of Medical Sciences. 
The inclusion criteria: Patients with definite diagnosis 
of TN according to the criteria of the International 
Headache Society (HIS) were included [HIS 3 with ICD-
10 (G44.0) coding]. Patients who were under standard 
pharmaceutical treatment for TN but had not experienced 
any improvement were also included. 
The exclusion criterion was pregnancy and patients with 
abnormal CBC and liver function tests. Patients were 
divided into 2 groups of cases and controls using block 
randomization. After the intervention in the 2 groups, the 
efficacy of treatment in terms of change in the severity 
of pain was assessed using the visual analog scale (VAS). 
The severity of pain was recorded prior to laser therapy, 
immediately after each session of laser therapy and one 
month after completion of treatment using the VAS. The 
pain scores were recorded in a questionnaire. The VAS 
ranged from 0-10; 10 indicated the most severe pain 
imaginable while 0 indicated no pain. Laser treatment 
was performed for 9 sessions, 3 days a week. 
Laser therapy was performed at the trigger points, based 
on previous studies we use laser and carbamazepine in 
case groups for treatment of TN. GaAlAs diode laser 
was irradiated at 810 nm wavelength with 5 J energy in 
continuous mode during 9 sessions using Thor device. 
The probe tip of the device was 1 cm in diameter and 
laser was irradiated for 25 seconds with maximum output 
power of 200 mW. If trigger point was not found, 2 to 3 
points were chosen in the path of pain indicated by patient 
and irradiated with laser. Laser therapy was performed by 
a technician. The statistical consultant was double blinded 
to the type of laser used for patients in the case group. 
Due to ethical considerations, patients in both groups 
were subjected to standard pharmaceutical therapy with 
100 mg carbamazepine at the onset of treatment and then 
another 100 mg after 2 days  based on severity of pain 
in patients. This process was continued until pain was 
alleviated taking into account the maximum safe dose 
of carbamazepine. Low level laser therapy (LLLT) along 
with pharmaceutical therapy was performed for the case 
group. Sham laser was used instead of LLLT in the control 
group.
Probe of the device was disinfected and covered with 
disposable covers prior to intraoral or extra oral use. For 
use of sham laser in the control group, the device was 
turned on but irradiation was not started (the start button 
was off). Since the device does not irradiate any visible 
light and has no pointer, the patients could not find out 
whether the device was on or off. 
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Assessment of the process of change in pain severity 
prior to treatment, at the end of treatment and one 
month after completion of treatment was done using 
repeated measures analysis of variance (ANOVA) with 
time of assessment as within subject factor and type of 
intervention (laser or sham laser) as between subject 
factor. 
Results 
A total of 30 patients participated in this study in 2 groups 
of 15; 36.67% were males and 63.33% were females (there 
were 33.33% males and 66.66% females in the case group 
and 40% males and 60% females in the control group) 
(Table 1). 
Pain severity in the 2 groups decreased with time (until 
the end of treatment) and this reduction was statistically 
significant (P = 0.003). Pain recurred at 4 months 
following completion of treatment and this change in 
pain score was statistically significant (P = 0.003, Table 2, 
Figure 1). In general, this difference was significant in any 
of the time points. The trend of change in pain score was 
significantly different between the 2 groups 
Although the severity of pain in the case group was less 
than that in the control group. The difference between 
the 2 groups was significant at any time point significant 
difference was noted in the trend of change in pain score 
between the 2 groups either.
Discussion 
Low level diode laser is extensively used for treatment 
of wounds, inflammation and chronic pain. Laser 
therapy was used in this study due to its analgesic, anti-
inflammatory and biological properties. Laser therapy 
regulates the blood flow and exerts its analgesic effects 
by decreasing the spasm of arterial muscles, which 
is required to enhance blood supply to the area. It 
increases the production of ATP and regulates the basic 
metabolism of tissues with limited source of energy to 
enhance oxygenation of hypoxic cells in trigger points. 
Another suggested mechanism for laser is its effect on the 
level of endorphins and subsequent pain control. Laser 
increases the level of endorphins and decreasing the level 
of serotonin. 
Only limited studies with case-control design have 
evaluated the effects of laser therapy on TN with 
controversial results. A few studies reported positive 
efficacy of laser therapy for treatment of TN while some 
others found no significant difference between laser and 
control groups. Based on these differences and suggestions 
regarding selection of particular wavelengths, sample size 
and blinding, this study was conducted to further evaluate 
this topic. 
In the current study, GaAlAs laser with 810 nm wavelength 
and 6.36 J/cm2 dose in continuous mode was used for 9 
sessions (3 sessions per week). Irradiation time was 25 
seconds and maximum power of device was 200 mW. 
Analgesic effects of laser in case group compared with 
control group was statistically significant. Our findings 
were not in line with those of Öz et al,24 Dundar et al,25 
Altan et al,26 and Hansen et al.27 The afore mentioned 
studies used different wavelengths and powers of laser 
and had different sample sizes and variable number of 
treatment sessions. However, they all had a case control 
design and yielded similar results. They all found no 
significant difference between the laser and control 
groups in terms of pain relief. A meta-analysis conducted 
by Fulop et al,28 reported the same results. 
Öz et al24 treated 20 patients with myofascial pain by 
820 nm low level diode laser with 3 J/cm2 energy density 
and 300 mW power twice a week (10 sessions). The 
control patients received an occlusal splint for 24 hours 
a day for 3 months. No significant difference was noted 
between the 2 groups and laser therapy was as effective as 
occlusal splint for treatment of myofascial pain.24 Hansen 
et al27 evaluated the efficacy of treatment of patients 
with different types of orofacial pain (oral dysesthesia, 
toothache, TN, TN secondary to trauma and tension 
headache) with diode infrared laser at 904 nm wavelength 
(OKA laser). In their double blind randomized controlled 
 
  
Figure 1. The Mean Severity of Pain in the 2 Groups at Different 
Time Points.
Table 1. Number (percentage) of Male and Female Patients in the 
2 Groups of Cases and Control
Group Male Female
Case 5 (33.33%) 10 (66.67%)
Control 6 (40%) 9 (60%)
Total 11 (36.67%) 19 (63.33%)
Table 2. The Mean (±Standard Deviation) Pain Score in the 2 
Groups at Different Time Points
Time of Assessment
Upon Completion of 
Treatment
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trial, laser with a constant or variable pulse repetition rate 
of 1 to 9999 Hz with 78.9 mW/cm2 power was used. Laser 
treatment was performed with 4.7 J/cm2 energy for 60 
seconds in the first 2 sessions. In case of no pain relief, 
laser was irradiated with 9.4 J/cm2 energy for 120 seconds 
in the next sessions. Treatment was continued for eight 
sessions during four weeks. No statistically significant 
difference was noted between the laser and sham laser 
groups. 
It should be noted that all the afore mentioned studies 
reported positive efficacy of laser therapy in decreasing 
the pain score (according to the VAS), which was also in 
line with our findings. 
Some previous studies did not mention the energy density 
of laser used. Some others chose energy densities over 20 
J/cm2 or lower than 5 J/cm2. Only a few studies chose a 
moderate energy density. Thus, we used 6.36 J/cm2 energy 
density. Carrasco et al29 used very high energy densities 
(25, 60, 105 J/cm2). Since they did not obtain favorable 
results and based on the suggested energy density values 
for GaAsAl laser,30 we used a lower energy density. In the 
study by Öz et al,24 3 J/cm2 and in the study by Hansen et 
al,27 4.7 and 9.4 J/cm2 energy densities were chosen. Based 
on their findings, we selected a higher energy density. 
To assess the stability of the results of laser therapy, VAS 
has been used in previous studies. Carrasco et al29 assessed 
the level of pain of patients using a VAS 15 days and 1 
month following completion of treatment. Dundar et al25 
used VAS 4 weeks after initiation of treatment and Altan et 
al26 used VAS at 0, 2, 12 and 14 weeks following treatment 
to assess the pain severity in patients. Despite variability 
in assessment time points, similar results were reported. 
In the current study, a slight increase in pain scores of 
patients (based on VAS) was noted after completion of 
treatment and one month after completion of treatment 
in the 2 groups and significant difference was noted. The 
laser therapy protocol was twice a week for 10 sessions by 
Öz et al,24 twice a week for 4 weeks by Carrasco et al,29 once 
a day for 15 days by Dundar et al,25 once a day for 10 days 
by Altan et al,26 and 8 sessions during 4 weeks by Hansen 
et al.28 Considering the fact that the effects of each session 
of laser therapy often last for nine to 72 hours and also to 
prevent the cumulative effects of laser, we performed laser 
therapy for 3 sessions a week. 
Since HeNe and GaAs laser was used in some previous 
studies with no significant difference between the case 
and control groups, GaAlAs laser was used in the current 
study. 
Carrasco et al,29 Shirani et al,31 Hakgüder et al,32 and 
Walker33 reported results that were similar to ours. They 
found significant differences between the case and control 
groups and reported superior efficacy of laser compared 
to the placebo. Carrasco et al29 treated patients with 
myofascial pain using 780 nm GaAlAs laser with 25, 60 
and 105 J/cm2 density in continuous mode twice a week 
for 4 weeks. Control groups were subjected to placebo 
laser therapy. A significant reduction in pain was noted 
in both groups with significant difference between the 2 
(P < 0.001).
These studies used a variety of laser types, densities, 
sample sizes and irradiation protocols. 
Walker33 evaluated the efficacy of repeated radiations 
of low level HeNe laser for chronic pain and reported 
optimal pain control. Of 26 patients with TN and 
neuralgia following herpes infection, 19 experienced pain 
relief with laser without taking any analgesics. No such a 
result was obtained in sham laser group. Laser therapy in 
their study was performed for 30 sessions (3 times a week) 
with HeNe laser at 632 nm wavelength, 1 mW power and 
20 Hz frequency for 20 seconds in an area measuring 
4 mm2.
Shirani et al31 used laser with 6.2 J/cm2 energy density 
twice a week for 3 weeks while Hakgüder et al32 used laser 
with 5 J/cm2 energy density. GaAlAs laser was used in both 
studies, which was similar the laser used in our study. The 
selected wavelength of laser by Shirani et al,31 Hakgüder 
et al,32 and Walker33 was within the effective wavelength 
range with adequate penetration depth for deep pains 
(650 to 1000 nm wavelengths have a penetration depth of 
20-40 mm).30 
Yang et al,34 IIbuldu et al,35 Pinheiro et al,36,37 and Gam 
et al38 performed interventional studies with one group. 
Our study was a double blind controlled clinical trial with 
one active control group. Due to ethical considerations, 
pharmaceutical therapy was performed in both groups. 
Sham laser was used in the control group instead of LLLT 
in order to eliminate the psychological effect of laser 
therapy as a confounding factor on the results. Yang et al34 
evaluated 16 patients with idiopathic facial pains. They 
used 800 nm diode laser with 105 J/cm2 energy density for 
10 sessions. The VAS showed a mean reduction in pain by 
43.87%. Pinheiro et al36,37 evaluated the effects of diode 
laser at 632.8 nm, 670 nm and 830 nm wavelengths with a 
radiated dose of 1.8 J/cm2 energy density on chronic pain 
such as TN, muscle pain and temporomandibular joint 
pain. Laser therapy was performed for 12 sessions, twice 
a week. The results showed optimal efficacy of laser for 
maxillofacial pain relief. The same group of researchers 
evaluated the efficacy of the same wavelengths of laser 
with the same protocol but with 2.5 J/cm2 energy density 
for maxillofacial pains (temporomandibular joint 
pain, TN, muscle pain, pain due to aphthous ulcer and 
inflammation and tooth hypersensitivity) and reported 
optimal analgesic efficacy of LLLT for maxillofacial 
pains.36,37 Gam et al,38 in a meta-analysis on the efficacy of 
LLLT for musculoskeletal pain concluded that it had no 
effect on pain due to musculoskeletal syndromes.
It is difficult to reach a conclusion regarding a specific 
dosage, wavelength or type of laser with the highest 
analgesic efficacy. In most cases, minimum dosage is not 
known and various doses have been reported for each 
type of laser. Selection of the most appropriate wavelength 
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is also difficult because the conclusions have been drawn 
mainly based on clinical experiences of the operators, and 
a widely accepted protocol does not exist in this regard. 
For instance, it has been suggested that laser therapy 
activates the somatosensory receptors and decreases 
regional pain perception, causing relaxation at the trigger 
points. However, this theory does not apply to deeper 
trigger points. Thus, variability in the results of studies 
may be explained by differences in laser parameters. 
Further studies are required on different types, 
wavelengths and energy densities of laser for trigger 
points at different depths in patients with TN. 
Conflict of Interests 
The authors declare that they have no conflict of interest. 
Ethical Considerations 
The study protocol was approved in the ethics committee 
of the university (code: IR.TUMS.VCR.REC.1395.498) 
and registered in the Iranian Registry of Clinical Trials 
website (identifier: IRCT201601142464N15, http://www.
irct.ir). All patients signed written informed consent 
forms.
References
1. Bagheri SC, Farhidvash F, Perciaccante VJ. Diagnosis and 
treatment of patients with trigeminal neuralgia. J Am Dent 
Assoc. 2004;135(12):1713-1717. 
2. Aguggia M. Typical facial neuralgias. Neurol Sci. 2005;26 
Suppl 2:s68-s70. doi:10.1007/s10072-005-0411-z.
3. De Leeuw R. Orofacial Pain. Chicago: Quintessence; 2008.
4. Krafft RM. Trigeminal neuralgia. Am Fam Physician. 
2008;77(9):1291-1296. 
5. Fauci AS. Harrison’s Principles of Internal Medicine: New 
York, NY: McGraw-Hill; 2008.
6. Matwychuk MJ. Diagnostic challenges of neuropathic 
tooth pain. J Can Dent Assoc. 2004;70(8):542-546. 
7. Peterson LJ, Ellis E, Hupp JR, Tucker MR. Contemporary 
Oral and Maxillofacial Surgery. Louis, MO: Mosby;  2003.
8. Levin LG, Law AS, Holland GR, Abbott PV, Roda RS. 
Identify and define all diagnostic terms for pulpal health 
and disease states. J Endod. 2009;35(12):1645-1657. 
doi:10.1016/j.joen.2009.09.032. 
9. Chamani G, Zarei MR, Mehrabani M, Taghiabadi Y. 
Evaluation of effects of Zingiber officinale on salivation in 
rats. Acta Med Iran. 2011;49(6):336-340. 
10. Neville B, Damm DD, Allen  C, Bouquot J. Epithelial 
Pathology Oral and Maxillofacial Pathology. 3rd ed. St. 
Louis: Elsevier; 2009:345.
11. Onwuekwe IO, Onodugo OD, Ezeala-Adikaibe B, et al. 
Pattern and presentation of epilepsy in Nigerian Africans: a 
study of trends in the southeast. Trans R Soc Trop Med Hyg. 
2009;103(8):785-789. doi:10.1016/j.trstmh.2009.04.010.
12. Headache Classification Subcommittee of the International 
Headache Society. The International Classification of 
Headache Disorders: 2nd ed. Cephalalgia. 2004;24 Suppl 
1:9-160.
13. Frost D, Hersh E, Levin L. Fonseca Oral and Maxillofacial 
Surgery. Philadelphia: Saunders; 2000.
14. Springhouse C. Professional’s Handbook of Drug Therapy 
in Pain Management. Lippincott Williams & Wilkins; 2001.
15. Weiner RS. Pain Management: A Practical Guide for 
Clinicians. Boca Raton, IL: CRC press; 2001.
16. Lewis PJ, Pollina J Jr. Neurosurgery Views. Neurosurgery. 
2005;2(1).
17. Antipa C, Moldoveanu V, Rusca N, Bruckner II, Podoleanu 
AG, Stanciulescu V, eds. Low-energy laser treatment 





18. Sweetman SC. Martindale: the complete drug reference: 
Pharmaceutical press; 2009.
19. Brondon P, Stadler I, Lanzafame RJ. Melanin density 
affects photobiomodulation outcomes in cell culture. 
Photomed Laser Surg. 2007;25(3):144-149. doi:10.1089/
pho.2007.2045. 
20. Antipa C, Pascu M-L, Pascu R, Ionescu E, eds. Objective 
methods in evaluating low-level laser therapy results. 




21. Ohno T. [Pain suppressive effect of low power laser 
irradiation. A quantitative analysis of substance P in the 
rat spinal dorsal root ganglion]. Nihon Ika Daigaku Zasshi. 
1997;64(5):395-400. 
22. Asnaashari M, Safavi N. Application of low level lasers in 
dentistry (endodontic). J Lasers Med Sci. 2013;4(2):57.
23. Amanat D, Ebrahimi H, Lavaee F, Alipour A. The 
adjunct therapeutic effect of lasers with medication in the 
management of orofacial pain: double blind randomized 
controlled trial. Photomed Laser Surg. 2013;31(10):474-
479. doi:10.1089/pho.2013.3555.
24. Öz S, Gokcen-Rohlig B, Saruhanoglu A, Tuncer EB. 
Management of myofascial pain: low-level laser therapy 
versus occlusal splints. J Craniofac Surg. 2010;21(6):1722-
1728. doi:10.1097/SCS.0b013e3181f3c76c.
25. Dundar U, Evcik D, Samli F, Pusak H, Kavuncu V. The 
effect of gallium arsenide aluminum laser therapy in the 
management of cervical myofascial pain syndrome: a 
double blind, placebo-controlled study. Clin Rheumatol. 
2007;26(6):930-934. doi:10.1007/s10067-006-0438-4.
26. Altan L, Bingol U, Aykac M, Yurtkuran M. Investigation of 
the effect of GaAs laser therapy on cervical myofascial pain 
syndrome. Rheumatol Int. 2005;25(1):23-27. doi:10.1007/
s00296-003-0396-y.
27. Hansen HJ, Thoroe U. Low power laser biostimulation of 
chronic oro-facial pain. A double-blind placebo controlled 
cross-over study in 40 patients. Pain. 1990;43(2):169-179. 
28. Fulop AM, Dhimmer S, Deluca JR, et al. A meta-analysis of 
the efficacy of laser phototherapy on pain relief. Clin J Pain. 
2010;26(8):729-736. doi:10.1097/AJP.0b013e3181f09713.
29. Carrasco TG, Guerisoli LD, Guerisoli DM, Mazzetto MO. 
Evaluation of low intensity laser therapy in myofascial 
pain syndrome. Cranio. 2009;27(4):243-247. doi:10.1179/
crn.2009.035.
Ebrahimi et al
 Journal of Lasers in Medical Sciences  Volume 9, Number 1, Winter 201868
30. Gholami GA, Fekrazad R, Esmaiel-Nejad A, Kalhori KA. An 
evaluation of the occluding effects of Er;Cr:YSGG, Nd:YAG, 
CO(2) and diode lasers on dentinal tubules: a scanning 
electron microscope in vitro study. Photomed Laser Surg. 
2011;29(2):115-121. doi:10.1089/pho.2009.2628.
31. Shirani AM, Gutknecht N, Taghizadeh M, Mir M. Low-level 
laser therapy and myofacial pain dysfunction syndrome: 
a randomized controlled clinical trial. Lasers Med Sci. 
2009;24(5):715-720. doi:10.1007/s10103-008-0624-5. 
32. Hakgüder A, Birtane M, Gurcan S, Kokino S, Turan FN. 
Efficacy of low level laser therapy in myofascial pain 
syndrome: an algometric and thermographic evaluation. 
Lasers Surg Med. 2003;33(5):339-343. doi:10.1002/
lsm.10241
33. Walker J. Relief from chronic pain by low power laser 
irradiation. Neurosci Lett. 1983;43(2-3):339-344. 
34. Yang HW, Huang YF. Treatment of persistent idiopathic 
facial pain (PIFP) with a low-level energy diode laser. 
Photomed Laser Surg. 2011;29(10):707-710. doi:10.1089/
pho.2011.3030.
35. Ilbuldu E, Cakmak A, Disci R, Aydin R. Comparison of laser, 
dry needling, and placebo laser treatments in myofascial 
pain syndrome. Photomed Laser Surg. 2004;22(4):306-311. 
doi:10.1089/pho.2004.22.306.
36. Pinheiro AL, Cavalcanti ET, Pinheiro TI, et al. Low-level 
laser therapy is an important tool to treat disorders of the 
maxillofacial region. J Clin Laser Med Surg. 1998;16(4):223-
226. doi:10.1089/clm.1998.16.223. 
37. Pinheiro AL, Cavalcanti ET, Pinheiro TI, Alves MJ, 
Manzi CT. Low-level laser therapy in the management 
of disorders of the maxillofacial region. J Clin Laser Med 
Surg. 1997;15(4):181-183. doi:10.1089/clm.1997.15.181. 
38. Gam AN, Thorsen H, Lonnberg F. The effect of low-level 
laser therapy on musculoskeletal pain: a meta-analysis. 
Pain. 1993;52(1):63-66.
